ALK B ALK-ABELLO A/S

Report on transactions with ALK-Abelló A/S B-shares and associated securities by managerial staff

Report on transactions with ALK-Abelló A/S B-shares and associated securities by managerial staff

ALK (ALKB:DC / OMX: ALK B / AKBLF): In accordance with article 19 in Regulation (EU) No 596/2014 of 16 April 2014 on market abuse (the Market Abuse Regulation), ALK-Abelló A/S shall report the following transactions by managerial staff as set forth in the attached announcement.

ALK-Abelló A/S

For further information please contact:

Investor Relations: Per Plotnikof, tel. , mobile

Media: Maiken Riise Andersen, tel.

Attachment



EN
27/08/2024

Underlying

ALK BALK-ABELLO A/S

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on ALK-ABELLO A/S

 PRESS RELEASE
Free
ALK B ALK-ABELLO A/S

Nine-month interim report (Q3) 2025 (unaudited) - English version only

Nine-month interim report (Q3) 2025 (unaudited) - English version only Bemærk venligst, at rapporten udelukkende forefindes på engelsk. ALK delivers 18% global organic revenue growth with operating profit up 41% in Q3 Results were better than expected, driven by a strong momentum for tablets, adrenaline autoinjectors, and SCIT/SLIT-drops. Operating profit increased as sales growth, improved gross margin, and optimisations yielded a profit margin of 28%. The full-year outlook has been upgraded.     Q3 performance highlights Comparative figures for Q3 2024 are shown in brackets. Growth ra...

8h / 26m 1 EN
 PRESS RELEASE
Free
ALK B ALK-ABELLO A/S

Nine-month interim report (Q3) 2025 (unaudited)

Nine-month interim report (Q3) 2025 (unaudited) ALK delivers 18% global organic revenue growth with operating profit up 41% in Q3 Results were better than expected, driven by a strong momentum for tablets, adrenaline autoinjectors, and SCIT/SLIT-drops. Operating profit increased as sales growth, improved gross margin, and optimisations yielded a profit margin of 28%. The full-year outlook has been upgraded.     Q3 performance highlights Comparative figures for Q3 2024 are shown in brackets. Growth rates are stated in local currencies (l.c.), unless otherwise indicated. Total revenue inc...

8h / 26m 1 EN
 PRESS RELEASE
Free
ALK B ALK-ABELLO A/S

ALK opjusterer forventningerne til 2025

ALK opjusterer forventningerne til 2025 Intern viden ALK (ALKB:DC / OMX: ALK B) har i dag annonceret, at forventningerne til helåret er blevet opjusteret på baggrund af resultaterne i tredje kvartal og udsigterne for resten af året. De ændrede forventninger afspejler primært det nuværende momentum i Europa. Omsætningen forventes nu at stige med 13-15% i lokale valutaer (mod tidligere: 12-14%) på baggrund af vækst i alle salgsregioner og i alle produktlinjer. Væksten vil primært være drevet af større volumener, da ALK forventer at behandle flere patienter med selskabets allergi-immunte...

8h / 31m 1 EN
 PRESS RELEASE
Free
ALK B ALK-ABELLO A/S

ALK upgrades its full-year outlook

ALK upgrades its full-year outlook Inside information ALK (ALKB:DC / OMX: ALK B) today announced that the 2025 full-year financial outlook has been upgraded based on the performance in Q3 and the outlook for the remainder of the year. The changes mainly reflect the current business momentum in Europe. Revenue is now expected to grow by 13-15% in local currencies (previously: 12-14%), driven by growth in all sales regions and product lines. Growth will predominantly be attributable to higher volumes, as ALK expects to treat more patients with its allergy immunotherapy (AIT) and anaphyla...

8h / 31m 1 EN
 PRESS RELEASE
Free
ALK B ALK-ABELLO A/S

Invitation til præsentation af ALK’s regnskab for de første ni måneder...

Invitation til præsentation af ALK’s regnskab for de første ni måneder (Q3) 2025 torsdag den 13. november 2025 ALK (ALKB.DC / OMX: ALK B) offentliggør delårsrapport for de første ni måneder (Q3) af 2025 om morgenen torsdag den 13. november 2025. ALK afholder senere samme dag kl. 13.30 en præsentation for investorer og analytikere, hvor ledelsen kommenterer på resultat og forventninger samt besvarer spørgsmål. ALK vil være repræsenteret ved Peter Halling, Adm. direktør, Claus Steensen Sølje, Finansdirektør og Per Plotnikof, IR-chef.  Live audio-webcast Mødet audiocastes live på , hvor g...

November 6, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch